Sanuwave Health (NASDAQ:SNWV) Given “Buy” Rating at Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of Sanuwave Health (NASDAQ:SNWV) in a research note released on Monday,Benzinga reports. They currently have a $47.00 price target on the stock, down from their previous price target of $53.00.

A number of other research analysts also recently commented on SNWV. Wall Street Zen downgraded shares of Sanuwave Health from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings raised Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Sanuwave Health presently has a consensus rating of “Buy” and a consensus target price of $51.00.

Sanuwave Health Price Performance

Sanuwave Health stock opened at $17.39 on Monday. Sanuwave Health has a 52-week low of $16.69 and a 52-week high of $46.58. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 10.08. The firm’s fifty day moving average is $23.83 and its 200 day moving average is $29.20. The company has a market cap of $149.38 million, a price-to-earnings ratio of -108.68 and a beta of 1.32.

Sanuwave Health (NASDAQ:SNWV) last issued its quarterly earnings data on Thursday, March 26th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14). Sanuwave Health had a negative return on equity of 141.56% and a net margin of 26.64%.The business had revenue of $13.09 million during the quarter, compared to analysts’ expectations of $13.23 million.

Institutional Investors Weigh In On Sanuwave Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of Sanuwave Health in the 2nd quarter worth about $26,000. BNP Paribas Financial Markets bought a new position in Sanuwave Health during the 2nd quarter valued at about $46,000. Police & Firemen s Retirement System of New Jersey bought a new position in Sanuwave Health during the 2nd quarter valued at about $52,000. Farther Finance Advisors LLC purchased a new stake in Sanuwave Health in the 3rd quarter worth about $57,000. Finally, Russell Investments Group Ltd. purchased a new stake in Sanuwave Health in the 3rd quarter worth about $67,000. Hedge funds and other institutional investors own 42.53% of the company’s stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.